A bispecific antibody that reengineers the way blood clots form is the focus of new clinical research published in the New England Journal of Medicine, with potential consequences for patients with inherited bleeding disorders.
The New England Journal of Medicine posted details of the research on its official X account, flagging a clinical implications paper by Flora Peyvandi, MD, PhD, examining how a bispecific antibody — a laboratory-engineered protein designed to bind two different targets at once — can effectively replicate the function of clotting factors that some patients are born without.
Coagulation (the process by which blood clots to stop bleeding) normally depends on a chain of proteins working in sequence. In conditions such as haemophilia A, one of those proteins — Factor VIII — is absent or deficient, leaving patients at risk of prolonged or internal bleeding. The antibody described in the research is designed to bridge two other proteins in that chain, bypassing the missing step.
This matters for patients who have developed inhibitors — antibodies of their own that neutralise standard clotting factor replacement therapy, making conventional treatment far less effective.
The paper sits within the journal’s hematology and genetics coverage. The New England Journal of Medicine is a peer-reviewed medical journal widely used by clinicians to inform treatment decisions, though research findings require assessment by specialist teams before changing individual patient care.
Kent residents living with haemophilia or related bleeding disorders are managed through NHS haematology services. Anyone with concerns about a bleeding condition should speak to their GP or contact NHS 111 for guidance on the right service to use.
Key information
- Speak to your GP if you have concerns about a bleeding or clotting condition
- NHS 111 is available 24 hours a day for non-emergency health queries
- For emergencies involving uncontrolled bleeding, call 999 immediately
Source: @NEJM